期刊
SCIENCE TRANSLATIONAL MEDICINE
卷 6, 期 224, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3007094
关键词
-
资金
- NCI NIH HHS [K23 CA163672, CA075115, CA129825, P01 CA104106, U01 CA152753, R01 CA075115, R01 CA057345, R01 CA129825, R37 CA057345, CA152753, T32 CA009071, CA62924, 5-T32-CA009071-25, R01 CA121113, CA43460, R01 CA148826, P30 CA006973, P50 CA062924, CA121113, R37 CA043460, CA57345, R29 CA075115, CA104106] Funding Source: Medline
- NIDCR NIH HHS [P50 DE019032] Funding Source: Medline
- NIGMS NIH HHS [T32 GM007309, T32 GM008752] Funding Source: Medline
The development of noninvasive methods to detect and monitor tumors continues to be a major challenge in oncology. We used digital polymerase chain reaction-based technologies to evaluate the ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types. We found that ctDNA was detectable in > 75% of patients with advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, hepatocellular, and head and neck cancers, but in less than 50% of primary brain, renal, prostate, or thyroid cancers. In patients with localized tumors, ctDNA was detected in 73, 57, 48, and 50% of patients with colorectal cancer, gastroesophageal cancer, pancreatic cancer, and breast adenocarcinoma, respectively. ctDNA was often present in patients without detectable circulating tumor cells, suggesting that these two biomarkers are distinct entities. In a separate panel of 206 patients with metastatic colorectal cancers, we showed that the sensitivity of ctDNA for detection of clinically relevant KRAS gene mutations was 87.2% and its specificity was 99.2%. Finally, we assessed whether ctDNA could provide clues into the mechanisms underlying resistance to epidermal growth factor receptor blockade in 24 patients who objectively responded to therapy but subsequently relapsed. Twenty-three (96%) of these patients developed one or more mutations in genes involved in the mitogen-activated protein kinase pathway. Together, these data suggest that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes in patients with multiple different types of cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据